

# CITATION REPORT

List of articles citing

**Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial**

**DOI: 10.7326/0003-4819-141-3-200408030-00005**  
**Annals of Internal Medicine, 2004, 141, 169-77.**

**Source:** <https://exaly.com/paper-pdf/37785000/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
237	Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications. <b>2004</b> , 13, 332-5		
236	Sightings. <i>High Altitude Medicine and Biology</i> , <b>2004</b> , 5, 389-394	1.9	
235	Therapie der pulmonalen Hypertonie. <b>2004</b> , 1, 95-101		2
234	Sildenafil voor meer prestatie op grote hoogte en lager?. <b>2004</b> , 42, 259-260		
233	Sildenafil for pulmonary hypertension. <b>2004</b> , CD003562		12
232	Two temporal components within the human pulmonary vascular response to approximately 2 h of isocapnic hypoxia. <i>Journal of Applied Physiology</i> , <b>2005</b> , 98, 1125-39	3.7	98
231	Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. <b>2005</b> , 112, 2980-5		260
230	Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage. <b>2005</b> , 68, 2131-42		75
229	Current treatment strategies for pulmonary arterial hypertension. <b>2005</b> , 258, 199-215		51
228	[Therapy of pulmonary arterial hypertension]. <b>2005</b> , 46, 341-9		0
227	Right and left ventricular adaptation to hypoxia: a tissue Doppler imaging study. <b>2005</b> , 289, H1391-8		73
226	Hypoxia impairs systemic endothelial function in individuals prone to high-altitude pulmonary edema. <b>2005</b> , 172, 763-7		111
225	Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. <b>2005</b> , 171, 275-81		193
224	Phosphodiesterase type 5 and high altitude pulmonary hypertension. <b>2005</b> , 60, 683-7		66
223	Consensus statement on chronic and subacute high altitude diseases. <i>High Altitude Medicine and Biology</i> , <b>2005</b> , 6, 147-57	1.9	353
222	Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. <b>2005</b> , 172, 105-13		266
221	Acute oxygen-sensing mechanisms. <b>2005</b> , 353, 2042-55		373

220	Physiological aspects of high-altitude pulmonary edema. <i>Journal of Applied Physiology</i> , <b>2005</b> , 98, 1101-1037	246
219	[The lung at high altitudes]. <b>2005</b> , 41, 537-9	2
218	High altitude medicine and biology advanced research workshop, Issyk-Kul, Kyrgyzstan, June 5-8, 2006. <i>High Altitude Medicine and Biology</i> , <b>2006</b> , 7, 315-8	1.9 3
217	Mediators and modulators of pulmonary arterial hypertension. <b>2006</b> , 291, L547-58	45
216	Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology. <b>2006</b> , 3, e290	145
215	Upregulated neurohumoral factors are associated with left ventricular remodeling and poor prognosis in rats with monocrotaline-induced pulmonary arterial hypertension. <b>2006</b> , 70, 1208-15	38
214	Effects of sildenafil on hypoxic pulmonary vascular function in dogs. <i>Journal of Applied Physiology</i> , <b>2006</b> , 101, 1085-90	3.7 28
213	Mortality in Relation to Smoking: 50 Years TObservations on Male British Doctors. <b>2006</b> , 2006, 498-500	1
212	Respiratory Physiology in Extreme Environments. <b>2006</b> , 13, 282-288	
211	Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia. <i>Journal of Applied Physiology</i> , <b>2006</b> , 100, 2031-40	3.7 104
210	Phosphodiesterase-5 inhibitors help climbers to achieve new heights. <b>2006</b> , 97, 672-3	2
209	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. <b>2006</b> , 5, 689-702	366
208	Dramatic beneficial effects of sildenafil in recurrent massive pulmonary embolism. <b>2006</b> , 32, 452-4	21
207	Short-term hypoxic exposure at rest and during exercise reduces lung water in healthy humans. <i>Journal of Applied Physiology</i> , <b>2006</b> , 101, 1623-32	3.7 49
206	Assessing and reducing the cardiac risk of noncardiac surgery. <b>2006</b> , 113, 1361-76	110
205	Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study. <b>2006</b> , 114, 1410-6	97
204	The practice of travel medicine: guidelines by the Infectious Diseases Society of America. <b>2006</b> , 43, 1499-539	195
203	Endothelin-1 and the pulmonary vascular response to altitude: a new therapeutic target?. <b>2006</b> , 114, 1350-1	15

202	Effects of sildenafil on exercise capacity in hypoxic normal subjects. <i>High Altitude Medicine and Biology</i> , <b>2007</b> , 8, 155-63	1.9	59
201	Chronic sildenafil lowers transpulmonary gradient and improves cardiac output allowing successful heart transplantation. <b>2007</b> , 9, 674-7		54
200	Safety of sildenafil in the treatment of erectile dysfunction in patients with obstructive sleep apnoea. <b>2007</b> , 6, 423-30		4
199	Expert opinion on available options treating pulmonary arterial hypertension. <b>2007</b> , 8, 2247-65		30
198	Pharmacotherapy of High-Altitude Illness. <b>2007</b> , 1, 129-141		1
197	Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. <b>2007</b> , 115, 2331-9		118
196	Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. <b>2007</b> , 15, 76-86		52
195	Pulmonary artery pressure in lymphangiomyomatosis: an echocardiographic study. <b>2007</b> , 132, 1573-8		64
194	High-altitude illnesses From the limited to the potentially lethal. <b>2007</b> , 20, 39-41		3
193	Effect of sildenafil on hypoxia-induced changes in pulmonary circulation and right ventricular function. <b>2007</b> , 159, 196-201		28
192	Clinical perspective of hypoxia-mediated pulmonary hypertension. <b>2007</b> , 9, 711-21		31
191	Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice. <b>2007</b> , 8, 15		78
190	Effects of acetazolamide on aerobic exercise capacity and pulmonary hemodynamics at high altitudes. <i>Journal of Applied Physiology</i> , <b>2007</b> , 103, 1161-5	3.7	36
189	Right ventricular function with hypoxic exercise: effects of sildenafil. <i>European Journal of Applied Physiology</i> , <b>2007</b> , 102, 87-95	3.4	22
188	Nonurologic applications of phosphodiesterase type 5 inhibitors. <b>2007</b> , 4, 64-70		1
187	Influence of sildenafil on lung diffusion during exposure to acute hypoxia at rest and during exercise in healthy humans. <i>European Journal of Applied Physiology</i> , <b>2008</b> , 103, 421-30	3.4	29
186	Update on high-altitude pulmonary edema: pathogenesis, prevention, and treatment. <b>2008</b> , 19, 293-303		81
185	Sildenafil improves the alveolar-capillary function in heart failure patients. <b>2008</b> , 126, 68-72		13

184	Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. <b>2008</b> , 21, 558-64		49
183	Is pulmonary gas exchange during exercise in hypoxia impaired with the increase of cardiac output?. <b>2008</b> , 33, 593-600		14
182	High hopes at high altitudes: pharmacotherapy for acute mountain sickness and high-altitude cerebral and pulmonary oedema. <b>2008</b> , 9, 119-27		31
181	Intravenous tezosentan and vardenafil attenuate acute hypoxic pulmonary hypertension. <i>High Altitude Medicine and Biology</i> , <b>2008</b> , 9, 223-7	1.9	10
180	Illnesses at high altitude. <b>2008</b> , 134, 402-416		90
179	Can intravenous endothelin-1 be used to enhance hypoxic pulmonary vasoconstriction in healthy humans?. <b>2008</b> , 101, 466-72		7
178	Phosphodiesterase-5 inhibition abolishes neuron apoptosis induced by chronic hypoxia independently of hypoxia-inducible factor-1alpha signaling. <b>2008</b> , 233, 1222-30		36
177	The Long-Acting Phosphodiesterase Inhibitor Tadalafil does not Influence AthletesT, Aerobic, and Anaerobic Thresholds in Normoxia. <b>2008</b> , 2008, 90-92		
176	Travelling to new heights: practical high altitude medicine. <b>2008</b> , 69, 348-52		5
175	Air to muscle O2 delivery during exercise at altitude. <i>High Altitude Medicine and Biology</i> , <b>2009</b> , 10, 123-34.9		85
174	Secondary prevention of HAPE in a Mount Everest summiteer. <i>High Altitude Medicine and Biology</i> , <b>2009</b> , 10, 293-6	1.9	7
173	Dexamethasone but not tadalafil improves exercise capacity in adults prone to high-altitude pulmonary edema. <b>2009</b> , 180, 346-52		54
172	Mountainside to bedside: reality or fiction?. <b>2009</b> , 3, 561-5		5
171	L-Arginine promotes angiogenesis in the chronically hypoxic lung: a novel mechanism ameliorating pulmonary hypertension. <b>2009</b> , 296, L1042-50		36
170	Prophylactic bosentan does not improve exercise capacity or lower pulmonary artery systolic pressure at high altitude. <b>2009</b> , 165, 123-30		15
169	Echocardiographic and tissue Doppler imaging of cardiac adaptation to high altitude in native highlanders versus acclimatized lowlanders. <b>2009</b> , 103, 1605-9		62
168	The effects of sildenafil and acetazolamide on breathing efficiency and ventilatory control during hypoxic exercise. <i>European Journal of Applied Physiology</i> , <b>2009</b> , 106, 509-15	3.4	16
167	[Therapy of pulmonary arterial hypertension]. <b>2009</b> , 50, 1101-2, 1104-9		2

166	Noninvasive detection of early pulmonary vascular dysfunction in scleroderma. <b>2009</b> , 103, 1713-8	28
165	Role of endothelin-1 in acute lung injury. <b>2009</b> , 153, 263-71	38
164	Bosentan decreases pulmonary vascular resistance and improves exercise capacity in acute hypoxia. <b>2009</b> , 135, 1215-1222	51
163	Poumon et altitude. <b>2010</b> , 7, 1-11	
162	Pathologies d'Altitude (dont gelures). <b>2010</b> , 5, 1-10	
161	Effects of acute hypoxia at moderate altitude on stroke volume and cardiac output during exercise. <b>2010</b> , 51, 170-5	20
160	Sildenafil attenuates pulmonary arterial pressure but does not improve oxygenation during ARDS. <b>2010</b> , 36, 758-64	34
159	Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. <b>2010</b> , 188, 115-23	59
158	Aktuelle Therapie der pulmonal-arteriellen Hypertonie. <b>2010</b> , 7, 192-199	
157	Prevention and treatment of high-altitude pulmonary edema. <b>2010</b> , 52, 500-6	56
156	Physiological adaptation of the cardiovascular system to high altitude. <b>2010</b> , 52, 456-66	228
155	What Limits Cardiac Performance during Exercise in Normal Subjects and in Healthy Fontan Patients?. <b>2010</b> , 2010,	61
154	Role of epidermal growth factor inhibition in experimental pulmonary hypertension. <b>2010</b> , 181, 158-67	99
153	Update on pulmonary hypertension 2009. <b>2010</b> , 181, 1020-6	12
152	Phosphodiesterase type 5 inhibitors for high-altitude pulmonary hypertension: a meta-analysis. <b>2010</b> , 30, 259-65	7
151	The effect of sildenafil citrate administration on selected physiological parameters of exercising Thoroughbred horses. <b>2010</b> , 42, 606-12	6
150	The impact of moderate-altitude staging on pulmonary arterial hemodynamics after ascent to high altitude. <i>High Altitude Medicine and Biology</i> , <b>2010</b> , 11, 139-45	1.9 18
149	Pro: Hypoxic pulmonary vasoconstriction is a limiting factor of exercise at high altitude. <i>High Altitude Medicine and Biology</i> , <b>2011</b> , 12, 309-12	1.9 13

148	Con: Hypoxic pulmonary vasoconstriction is not a limiting factor of exercise at high altitude. <i>High Altitude Medicine and Biology</i> , <b>2011</b> , 12, 313-7	1.9	8
147	Pulse oximetry at high altitude. <i>High Altitude Medicine and Biology</i> , <b>2011</b> , 12, 109-19	1.9	65
146	Patologie da alte quote (tra cui geloni). <b>2011</b> , 15, 1-10		
145	Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo-controlled trial. <i>High Altitude Medicine and Biology</i> , <b>2011</b> , 12, 207-14	1.9	27
144	Sildenafil and bosentan improve arterial oxygenation during acute hypoxic exercise: a controlled laboratory trial. <b>2011</b> , 22, 211-21		16
143	Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. <b>2011</b> , 118, 855-64		179
142	Fit for high altitude: are hypoxic challenge tests useful?. <b>2011</b> , 6, 38-46		9
141	Ischemic preconditioning of the lower extremity attenuates the normal hypoxic increase in pulmonary artery systolic pressure. <b>2011</b> , 179, 248-53		30
140	Horse metabolism and the photocatalytic process as a tool to identify metabolic products formed from dopant substances: the case of sildenafil. <b>2011</b> , 3, 724-34		15
139	No protective role for hypoxic pulmonary vasoconstriction in severe hypergravity-induced arterial hypoxemia. <i>European Journal of Applied Physiology</i> , <b>2011</b> , 111, 2099-104	3.4	1
138	Sildenafil does not improve steady state cardiovascular hemodynamics, peak power, or 15-km time trial cycling performance at simulated moderate or high altitudes in men and women. <i>European Journal of Applied Physiology</i> , <b>2011</b> , 111, 3031-40	3.4	18
137	Dexamethasone improves maximal exercise capacity of individuals susceptible to high altitude pulmonary edema at 4559 m. <i>High Altitude Medicine and Biology</i> , <b>2011</b> , 12, 169-77	1.9	23
136	Inhaled whole exhaust and its effect on exercise performance and vascular function. <b>2011</b> , 23, 658-67		46
135	Sildenafil has little influence on cardiovascular hemodynamics or 6-km time trial performance in trained men and women at simulated high altitude. <i>High Altitude Medicine and Biology</i> , <b>2011</b> , 12, 215-22	1.9	18
134	Air travel can be safe and well tolerated in patients with clinically stable pulmonary hypertension. <b>2011</b> , 1, 239-43		17
133	The phosphodiesterases type 5 inhibitor tadalafil reduces the activation of the hypothalamus-pituitary-adrenal axis in men during cycle ergometric exercise. <b>2012</b> , 302, E972-8		14
132	Pulmonary circulation at exercise. <b>2012</b> , 2, 711-41		110
131	Cardiac uses of phosphodiesterase-5 inhibitors. <b>2012</b> , 59, 9-15		65

130	Hypoxic pulmonary vasoconstriction. <b>2012</b> , 92, 367-520		444
129	Andrological aspects of physical exercise and sport medicine. <b>2012</b> , 42, 278-84		47
128	High-altitude pulmonary edema. <b>2012</b> , 2, 2753-73		76
127	Mechanisms of exercise-induced pulmonary hypertension in patients with cardiac septal defects. <b>2012</b> , 33, 782-90		6
126	Effects of epoprostenol and sildenafil on right ventricular function in hypoxic volunteers: a tissue Doppler imaging study. <i>European Journal of Applied Physiology</i> , <b>2012</b> , 112, 1285-94	3-4	15
125	The ethics of neuroenhancement. <b>2013</b> , 118, 323-34		26
124	Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions. <b>2013</b> , 126, 192-9		25
123	Effects of garlic consumption on physiological variables and performance during exercise in hypoxia. <b>2013</b> , 38, 363-7		4
122	Pulmonary vascular reserve and exercise capacity at sea level and at high altitude. <i>High Altitude Medicine and Biology</i> , <b>2013</b> , 14, 19-26	1.9	17
121	Hypovolemia explains the reduced stroke volume at altitude. <b>2013</b> , 1, e00094		25
120	Lung membrane conductance and capillary volume derived from the NO and CO transfer in high-altitude newcomers. <i>Journal of Applied Physiology</i> , <b>2013</b> , 115, 157-66	3-7	23
119	Prevention, assessment and management of altitude sickness. <b>2013</b> , 3, 86-91		
118	Shunt volume dynamics in stroke patients with patent foramen ovale. <i>Journal of Applied Physiology</i> , <b>2013</b> , 115, 704-7	3-7	
117	Recent strategies in treatment of pulmonary arterial hypertension, a review. <b>2015</b> , 7, 307-22		16
116	Adjunctive treatments in pediatric acute respiratory distress syndrome. <b>2014</b> , 8, 703-16		9
115	rs-A680T variant in GUCY1A3 as a candidate conferring protection from pulmonary hypertension among Kyrgyz highlanders. <b>2014</b> , 7, 920-9		20
114	Ischemic preconditioning improves oxygen saturation and attenuates hypoxic pulmonary vasoconstriction at high altitude. <i>High Altitude Medicine and Biology</i> , <b>2014</b> , 15, 155-61	1.9	34
113	Canadian Academy of Sport and Exercise Medicine position statement: athletes at high altitude. <b>2014</b> , 24, 120-7		14



112	High-Altitude Pulmonary Edema (HAPE). <b>2014</b> , 405-427		
111	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. <i>Global Cardiology Science &amp; Practice</i> , <b>2014</b> , 2014, 257-90	0.7	10
110	Predictors of sildenafil effects on exercise capacity in adolescents and adults with Fontan circulation. <b>2014</b> , 103, 641-6		12
109	Meta-analysis of clinical efficacy of sildenafil, a phosphodiesterase type-5 inhibitor on high altitude hypoxia and its complications. <i>High Altitude Medicine and Biology</i> , <b>2014</b> , 15, 46-51	1.9	18
108	Deletion of the von Hippel-Lindau gene causes sympathoadrenal cell death and impairs chemoreceptor-mediated adaptation to hypoxia. <b>2014</b> , 6, 1577-92		39
107	Impaired myocardial function does not explain reduced left ventricular filling and stroke volume at rest or during exercise at high altitude. <i>Journal of Applied Physiology</i> , <b>2015</b> , 119, 1219-27	3.7	29
106	High-altitude illnesses. <b>2015</b> , 363-367		
105	Effect of oral nitrate supplementation on pulmonary hemodynamics during exercise and time trial performance in normoxia and hypoxia: a randomized controlled trial. <i>Frontiers in Physiology</i> , <b>2015</b> , 6, 288	4.6	37
104	Wilderness medicine at high altitude: recent developments in the field. <b>2015</b> , 6, 319-28		20
103	Regulation of cardiac output in hypoxia. <b>2015</b> , 25 Suppl 4, 53-9		45
102	Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. <b>2015</b> , 132, 2037-99		624
101	High altitude-induced borderline pulmonary hypertension impaired cardiorespiratory fitness in healthy young men. <b>2015</b> , 181, 382-8		19
100	Physiology in Medicine: A physiologic approach to prevention and treatment of acute high-altitude illnesses. <i>Journal of Applied Physiology</i> , <b>2015</b> , 118, 509-19	3.7	40
99	High-altitude headache. <b>2015</b> , 19, 483		14
98	Acute resolution of pulmonary alveolar infiltrates in 10 dogs with pulmonary hypertension treated with sildenafil citrate: 2005-2014. <b>2015</b> , 17, 182-91		34
97	Ischemic preconditioning does not improve peak exercise capacity at sea level or simulated high altitude in trained male cyclists. <b>2015</b> , 40, 65-71		28
96	Day-to-day variability in cardiorespiratory responses to hypoxic cycle exercise. <b>2015</b> , 40, 155-61		7
95	Cardiac output during exercise: a comparison of four methods. <b>2015</b> , 25, e20-7		54

94	Altitude-Induced Pulmonary Hypertension on One-Day Rapid Ascent of Mount Fuji: Incidence and Therapeutic Effects of Sildenafil. <b>2016</b> , 33, 838-43		4
93	Increased consumption and vasodilatory effect of nitrite during exercise. <b>2016</b> , 310, L354-64		5
92	Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan. <b>2016</b> , 27, 66-70		7
91	Sildenafil and Exercise Capacity in the Elderly at Moderate Altitude. <b>2016</b> , 27, 307-15		10
90	Drug Use and Misuse in the Mountains: A UIAA MedCom Consensus Guide for Medical Professionals. <i>High Altitude Medicine and Biology</i> , <b>2016</b> , 17, 157-184	1.9	13
89	Contribution of sport science to performance: Wheelchair rugby. <b>2016</b> , 172-198		
88	Medication Use Among Mount Everest Climbers: Practice and Attitudes. <i>High Altitude Medicine and Biology</i> , <b>2016</b> , 17, 315-322	1.9	8
87	Association between smoking and the risk of acute mountain sickness: a meta-analysis of observational studies. <b>2016</b> , 3, 37		4
86	Can sildenafil improve physical performance at altitude? Current scientific evidence. <b>2016</b> , 51, 27-35		
85	Hypoxic pulmonary hypertension in chronic lung diseases: novel vasoconstrictor pathways. <b>2016</b> , 4, 225-36		40
84	Enhanced muscular oxygen extraction in athletes exaggerates hypoxemia during exercise in hypoxia. <i>Journal of Applied Physiology</i> , <b>2016</b> , 120, 351-61	3.7	17
83	Pulmonary capillary reserve and exercise capacity at high altitude in healthy humans. <i>European Journal of Applied Physiology</i> , <b>2016</b> , 116, 427-37	3.4	12
82	Of Deep Waters and Thin Air: Pulmonary Edema in Swimmers Versus Mountaineers. <b>2016</b> , 133, 951-3		5
81	High Altitude. <b>2016</b> , 1367-1384.e4		2
80	Right ventricle dimensions and function in response to acute hypoxia in healthy human subjects. <b>2017</b> , 219, 478-485		14
79	Changes in acute pulmonary vascular responsiveness to hypoxia during a progressive ascent to high altitude (5300m). <b>2017</b> , 102, 711-724		22
78	Pulmonary Vascular Function and Aerobic Exercise Capacity at Moderate Altitude. <b>2017</b> , 49, 2131-2138		9
77	Cardiovascular Effects of Performance-Enhancing Drugs. <b>2017</b> , 135, 89-99		24

76	Effect of hypoxia and hyperoxia on exercise performance in healthy individuals and in patients with pulmonary hypertension: a systematic review. <i>Journal of Applied Physiology</i> , <b>2017</b> , 123, 1657-1670	3.7	14
75	Phosphodiesterase Type 5 Inhibitors, Sport and Doping. <b>2017</b> , 16, 443-447		11
74	The principal pathways involved in the in vivo modulation of hypoxic pulmonary vasoconstriction, pulmonary arterial remodelling and pulmonary hypertension. <b>2017</b> , 219, 728-756		49
73	EFFECTS OF MODEST IRON LOADING ON IRON INDICES IN HEALTHY INDIVIDUALS. <i>Journal of Applied Physiology</i> , <b>2018</b> ,	3.7	2
72	Daily Chronic Intermittent Hypobaric Hypoxia Does Not Induce Chronic Increase in Pulmonary Arterial Pressure Assessed by Echocardiography. <b>2018</b> , 2018, 9649716		
71	The independent effects of hypovolaemia and pulmonary vasoconstriction on ventricular function and exercise capacity during acclimatisation to 3800m. <b>2019</b> , 597, 1059-1072		25
70	Getting to the heart of the matter: understanding cardiovascular limitations at high altitude. <b>2019</b> , 597, 987		1
69	Exercise, training, and the hypothalamic-pituitary-gonadal axis in men. <b>2019</b> , 9, 86-89		
68	The Complexity of Diagnosing High-Altitude Pulmonary Edema: A Case Report and Review of the Differential Diagnosis of Greater Than Expected Hypoxemia at Altitude. <i>High Altitude Medicine and Biology</i> , <b>2019</b> , 20, 181-186	1.9	2
67	Intravenous iron delivers a sustained (8-week) lowering of pulmonary artery pressure during exercise in healthy older humans. <b>2019</b> , 7, e14164		6
66	Sildenafil does not improve performance in 16.1 km cycle exercise time-trial in acute hypoxia. <i>PLoS ONE</i> , <b>2019</b> , 14, e0210841	3.7	5
65	Sildenafil enhances central hemodynamic responses to exercise, but not V <sub>o</sub> , in people with diabetes mellitus. <i>Journal of Applied Physiology</i> , <b>2019</b> , 127, 1-10	3.7	1
64	High-Altitude Medicine. <b>2019</b> , 387-400		5
63	Sildenafil does not reliably improve exercise performance in hypoxia: a systematic review. <b>2019</b> , 5, e000526		2
62	Pulmonary Vascular Reserve and Aerobic Exercise Capacity. <b>2019</b> ,		1
61	Phosphodiesterase 5 inhibitors for pulmonary hypertension. <b>2019</b> , 1, CD012621		32
60	Perfusion of Intrapulmonary Arteriovenous Anastomoses Is Not Related to VO <sub>2</sub> in Hypoxia and Is Unchanged by Oral Sildenafil. <i>High Altitude Medicine and Biology</i> , <b>2019</b> , 20, 399-406	1.9	
59	Ischemic Preconditioning, O <sub>2</sub> Kinetics, and Performance in Normoxia and Hypoxia. <b>2019</b> , 51, 900-911		11

58	Putative Role of Respiratory Muscle Training to Improve Endurance Performance in Hypoxia: A Review. <i>Frontiers in Physiology</i> , <b>2018</b> , 9, 1970	4.6	9
57	Pulmonary hypertension in chronic lung disease and hypoxia. <b>2019</b> , 53,		231
56	Emerging Mechanisms of Pulmonary Vasoconstriction in SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) and Potential Therapeutic Targets. <b>2020</b> , 21,		17
55	Cardiovascular Side Effects of Commonly Prescribed Medications and Performance Enhancing Drugs and Special Considerations for the Athlete. <b>2020</b> , 513-530		1
54	Right Ventricular Structure and Function During Exercise. <b>2021</b> , 85-102		
53	High Altitude and the Right Ventricle. <b>2021</b> , 171-181		
52	Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders. <b>2021</b> , 18,		7
51	Re: "Meta-Analysis of Clinical Efficacy of Sildenafil, a Phosphodiesterase Type-5 Inhibitor on High Altitude Hypoxia and Its Complications" by Xu et al. <i>High Altitude Medicine and Biology</i> , <b>2021</b> , 22, 107-108 <sup>1-9</sup>		
50	Modelling the relationships between arterial oxygen saturation, exercise intensity and the level of aerobic performance in acute hypoxia. <i>European Journal of Applied Physiology</i> , <b>2021</b> , 121, 1993-2003	3.4	3
49	A randomized controlled trial of enhancing hypoxia-mediated right cardiac mechanics and reducing afterload after high intensity interval training in sedentary men. <b>2021</b> , 11, 12564		2
48	High-altitude illnesses. <b>2021</b> , 410-415		
47	Implication of Blood Rheology and Pulmonary Hemodynamics on Exercise-Induced Hypoxemia at Sea Level and Altitude in Athletes. <b>2021</b> , 31, 397-405		1
46	Clinical Implications for Exercise at Altitude Among Individuals With Cardiovascular Disease: A Scientific Statement From the American Heart Association. <b>2021</b> , 10, e023225		2
45	Group 3 PH: Clinical Features and Treatment. <b>2022</b> , 678-690		
44	Biventricular function at high altitude: implications for regulation of stroke volume in chronic hypoxia. <b>2007</b> , 618, 13-24		11
43	Right Ventricular Structure and Function During Exercise. <b>2014</b> , 83-98		2
42	High-Altitude Medicine. <b>2007</b> , 2-36		14
41	Pulmonary Vascular Disease. <b>2010</b> , 1147-1161		1

40	Reversal of experimental pulmonary hypertension by PDGF inhibition. <b>2005</b> , 115, 2811-21		764
39	Exercise Intolerance in Cystic Fibrosis: Importance of Skeletal Muscle. <b>2021</b> , 53, 684-693		1
38	Effects of sildenafil citrate on peripheral fatigue and exercise performance after exhaustive swimming exercise in rats. <i>Journal of Exercise Rehabilitation</i> , <b>2019</b> , 15, 751-756	1.8	3
37	Ups and downs of Viagra: revisiting ototoxicity in the mouse model. <i>PLoS ONE</i> , <b>2013</b> , 8, e79226	3.7	14
36	Anti-hypotensive treatment and endothelin blockade synergistically antagonize exercise fatigue in rats under simulated high altitude. <i>PLoS ONE</i> , <b>2014</b> , 9, e99309	3.7	7
35	Drug Use on Mont Blanc: A Study Using Automated Urine Collection. <i>PLoS ONE</i> , <b>2016</b> , 11, e0156786	3.7	12
34	Sildenafil in the treatment of pulmonary hypertension. <i>Vascular Health and Risk Management</i> , <b>2006</b> , 2, 411-22	4.4	88
33	Group 3 pulmonary hypertension: Challenges and opportunities. <i>Global Cardiology Science &amp; Practice</i> , <b>2020</b> , 2020, e202006	0.7	3
32	High-Altitude Illness in Children. <i>Pediatric Annals</i> , <b>2009</b> , 38,	1.3	6
31	Nifedipine and Amlodipine Are Associated With Improved Mortality and Decreased Risk for Intubation and Mechanical Ventilation in Elderly Patients Hospitalized for COVID-19. <i>Cureus</i> , <b>2020</b> , 12, e8069	1.2	50
30	NO pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. <b>2004</b> , 163-168		
29	Treatment of Pulmonary Hypertension Related to Disorders of Hypoxia. <i>Advances in Pulmonary Hypertension</i> , <b>2005</b> , 4, 14-22	0.5	
28	High Altitude Pulmonary Edema. <b>2006</b> , 288-304		
27	Erectile Dysfunction and Cardiovascular Disease. <b>2007</b> , 2791-2801		
26	Lungengefäßkrankungen. <b>2008</b> , 433-528		
25	High-altitude Medicine. <b>2008</b> , 393-404		
24	High Altitude. <b>2010</b> , 1651-1673		2
23	High-Altitude Medicine. <b>2010</b> , 1917-1928		

22	High-Altitude Pulmonary Edema. <b>2011</b> , 871-888		
21	Phosphodiesterase Inhibitors in the Treatment of Pulmonary Hypertension. <b>2011</b> , 1477-1485		
20	Physical and Chemical Injuries of the Lung. <b>2012</b> , 574-581		
19	High-Altitude Medicine. <b>2013</b> , 361-372		
18	Exercise. <b>2014</b> , 301-323		
17	Hypoxic Pulmonary Hypertension. <i>Respiratory Medicine</i> , <b>2015</b> , 67-92	0.2	
16	Effect of Sildenafil Citrate on Exercise Capacity in Athletes With Spinal Cord Injury. <i>International Journal of Sports Physiology and Performance</i> , <b>2020</b> , 1-5	3.5	1
15	Effect of sildenafil citrate on brain central fatigue after exhaustive swimming exercise in rats. <i>Journal of Exercise Rehabilitation</i> , <b>2019</b> , 15, 651-656	1.8	2
14	Impact of Altitude on Cardiopulmonary and Right Ventricular Hemodynamics During Exercise. <i>Advances in Pulmonary Hypertension</i> , <b>2020</b> , 19, 77-79	0.5	
13	Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. <i>Experimental and Clinical Cardiology</i> , <b>2011</b> , 16, e30-5		39
12	Cardiovascular effects of doping substances, commonly prescribed medications and ergogenic aids in relation to sports: a position statement of the sport cardiology and exercise nucleus of the European Association of Preventive Cardiology.. <i>European Journal of Preventive Cardiology</i> , <b>2022</b> ,	3.9	5
11	Right Ventricular Response to Acute Hypoxia Exposure: A Systematic Review.. <i>Frontiers in Physiology</i> , <b>2021</b> , 12, 786954	4.6	
10	Inhaled nitric oxide does not improve maximal oxygen consumption in endurance trained and untrained healthy individuals.. <i>European Journal of Applied Physiology</i> , <b>2022</b> , 122, 703	3.4	0
9	Table_1.DOCX. <b>2019</b> ,		
8	Effects of acetazolamide on pulmonary artery pressure and prevention of high altitude pulmonary edema after rapid active ascent to 4,559 m.. <i>Journal of Applied Physiology</i> , <b>2022</b> ,	3.7	1
7	Is sildenafil a doping drug in hypoxic conditions?. <i>Aging Male</i> , <b>2022</b> , 25, 156-158	2.1	
6	Relaxin does not prevent development of hypoxia-induced pulmonary edema in rats. <i>Pflugers Archiv European Journal of Physiology</i> ,	4.6	0
5	Clinician's Corner: Counseling Patients with Pulmonary Vascular Disease Traveling to High Altitude. <i>High Altitude Medicine and Biology</i> ,	1.9	0

- 4 A change of heart: mechanisms of cardiac adaptation to acute and chronic hypoxia.
- 3 Inhaled moslicigat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC. **2022**, 23, ○
- 2 Exogenous Ketone Supplements in Athletic Contexts: Past, Present, and Future. 1
- 1 Effect of High-Altitude Exposure on the Heart. **2023**, 3, 48-53 ○